Cart
No products in the cart.
https://shoppeblack.us/
Acclinate, a Birmingham, Alabama-based company, has secured a significant $7 million Series A funding round. Led by Cencora Ventures with contributions from Labcorp and Latimer Ventures, this investment fuels Acclinate’s mission to empower underserved communities and transform healthcare equity.
Acclinate’s approach breaks the mold of traditional clinical trial recruitment. They focus on building trust and fostering long-term engagement with diverse communities. This is achieved through culturally sensitive education and outreach programs. Their platform, NOWINCLUDED, provides a safe space for individuals to learn about health issues, clinical trials, and the importance of representation in medical research.
But Acclinate goes beyond simple information sharing. They leverage data and analytics to personalize the experience for each user. This ensures individuals receive targeted information and resources relevant to their health background and interests. This fosters a sense of ownership and transforms them into active participants in their health journey.
The data generated from this community engagement is another crucial aspect of Acclinate’s approach. They translate this data into actionable insights through their e-DICT (Enhanced Diversity in Clinical Trials) platform.
This powerful tool utilizes predictive analytics technology to track user interest and report on community engagement at the individual level. This empowers organizations to:
The $7 million funding round will propel Acclinate’s growth and further enhance its data-driven approach. This benefits not only patients from diverse backgrounds who have a greater chance to participate in research and see themselves reflected in medical advancements, but also pharmaceutical companies.
By facilitating a more inclusive clinical trial landscape, e-DICT helps companies gain access to a richer pool of data, ultimately leading to the development of safer and more effective treatments that work for everyone.
Acclinate’s story is one of innovation and social impact. This investment marks a significant step towards a future where clinical trials are truly inclusive, healthcare is accessible to all, and diverse communities have a rightful voice in shaping the future of medicine.
In addition to its core platform, Acclinate offers a suite of services to further support organizations in their diversity efforts, including the Affective Trust Framework and custom training programs.
By combining community engagement with cutting-edge data analysis, Acclinate is paving the way for a future where clinical trials are truly representative of the populations they serve.
The post Acclinate Secures $7 Million to Revolutionize Health Equity and Clinical Trial Diversity appeared first on SHOPPE BLACK.